CHAPEL HILL, N.C., June 22, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced thatPrabhavathi Fernandes, president and chief executive officer, will present at the 2011 Wells Fargo Healthcare Conference at 1 p.m. EDT, June 23, 2011, in Boston. Dr. Fernandes will provide an overview of the company’s two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and other infections and TAKSTA for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com
Tony Russo, Ph.D.
Russo Partners LLC
(212) 845-4251
Tony.russo@russopartnersllc.com
SOURCE Cempra Pharmaceuticals Inc.
